Telomerase activity and telomerase subunits gene expression patterns in neuroblastoma: A molecular and immunohistochemical study establishing prognostic tools for fresh-frozen and paraffin-embedded tissues

Journal of Clinical Oncology

Volumn 18, Issue 13, 2000, Pages 2582-2592

  Poremba, Christopher ^a   Scheel, Christina ^a   Hero, Barbara ^a   Christiansen, Holger ^a   Schaefer, Karl Ludwig ^a   Nakayama, Jun Ichi ^a   Berthold, Frank ^a   Juergens, Heribert ^a   Boecker, Werner ^a   Dockhorn Dworniczak, Barbara ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

TELOMERASE;

ARTICLE; CHILD; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME SUBUNIT; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; MAJOR CLINICAL STUDY; MALE; NEUROBLASTOMA; NUCLEOTIDE SEQUENCE; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCHOOL CHILD;

EID: 0033934869     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.13.2582     Document Type: Article

References (39)

1. Maris JM, Matthay KK: Molecular biology of neuroblastoma. J Clin Oncol 17:2264-2279, 1999
2. Woods WG, Lemieux B, Tuchman M: Neuroblastoma represents distinct clinical-biologic entities: A review and perspective from the Quebec Neuroblastoma Screening Project. Pediatrics 89:114-118, 1992
3. Gallego S, Parareda A, Munell F, et al: Clinical relevance of molecular markers in neuroblastoma: Results from a single institution. Oncol Rep 6:891-896, 1999
4. Erttmann R, Tafese T, Berthold F, et al: 10 years' neuroblastoma screening in Europe: Preliminary results of a clinical and biological review from the Study Group for Evaluation of Neuroblastoma Screening in Europe (SENSE). Eur J Cancer 34:1391-1397, 1998
5. Schwab M: Amplification of N-myc as a prognostic marker for patients with neuroblastoma. Semin Cancer Biol 4:13-18, 1993
6. Christiansen H, Lampert F: Tumour karyotype discriminates between good and bad prognostic outcome in neuroblastoma. Br J Cancer 57:121-126, 1988
7. Brodeur GM, Seeger RC, Schwab M, et al: Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224:1121-1124, 1984
8. Bown N. Cotterill S, Lastowska M, et al: Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 340:1954-1961, 1999
9. Brinkschmidt C, Poremba C, Christiansen H, et al: Comparative genomic hybridization and telomerase activity analysis identify two biologically different groups of 4s neuroblastomas. Br J Cancer 77:2223-2229, 1998
10. Poremba C, Shroyer KR, Frost M, et al: Telomerase is a highly sensitive and specific molecular marker in fine-needle aspirates of breast lesions. J Clin Oncol 17:2020-2026, 1999
11. Schneider-Stock R, Epplen JT, Walter H, et al: Telomeric lengths and telomerase activity in liposarcomas. Mol Carcinog 24:144-151, 1999
12. Umbricht CB, Sherman ME, Dome J, et al: Telomerase activity in ductal carcinoma in situ and invasive breast cancer. Oncogene 18:3407-3414, 1999
13. Shay JW, Bacchetti S: A survey of telomerase activity in human cancer. Eur J Cancer 33:787-791, 1997
14. Hiyama E, Hiyama K, Yokoyama T, et al: Correlating telomerase activity levels with human neuroblastoma outcomes [see comments]. Nat Med 1:249-255, 1995
15. Poremba C, Willenbring H, Hero B, et al: Telomerase activity distinguishes between neuroblastomas with good and poor prognosis. Ann Oncol 10:715-721, 1999
16. Takakura M, Kyo S, Kanaya T, et al: Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res 59:551-557, 1999
17. Ramakrishnan S, Eppenberger U, Mueller H, et al: Expression profile of the putative catalytic subunit of the telomerase gene. Cancer Res 58:622-625, 1998
18. Meyerson M, Counter CM, Eaton EN, et al: hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 90:785-795, 1997
19. Sumida T, Hamakawa H, Sogawa K, et al: Telomerase components as a diagnostic tool in human oral lesions. Int J Cancer 80:1-4, 1999
20. Ito H, Kyo S, Kanaya T, et al: Expression of human telomerase subunits and correlation with telomerase activity in urothelial cancer. Clin Cancer Res 4:1603-1608, 1998
21. Avilion AA, Piatyszek MA, Gupta J, et al: Human telomerase RNA and telomerase activity in immortal cell lines and tumor tissues. Cancer Res 56:645-650, 1996
22. Berthold F: Neuroblastom, in Schmoll HJ, Höffken K, Possinger K (eds): Kompendium Internistische Onkologie (ed 2). Heidelberg, Germany, Springer, 1997, pp 1805-1819
23. Poremba C, Bocker W, Willenbring H, et al: Telomerase activity in human proliferative breast lesions. Int J Oncol 12:641-648, 1998
24. Tahara H, Yasui W, Tahara E, et al: Immuno-histochemical detection of human telomerase catalytic component, hTERT, in human colorectal tumor and non-tumor tissue sections. Oncogene 18:1561-1567, 1999
25. Hiyama E, Hiyama K, Yokoyama T, et al: Length of telomeric repeats in neuroblastoma: Correlation with prognosis and other biological characteristics. Jpn J Cancer Res 83:159-164, 1992
26. Shapiro DN, Valentine MB, Rowe ST, et al: Detection of N-myc gene amplification by fluorescence in situ hybridization: Diagnostic utility for neuroblastoma. Am J Pathol 142:1339-1346, 1993
27. Katzenstein HM, Bowman LC, Brodeur GM, et al: Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: The Pediatric Oncology Group experience - A Pediatric Oncology Group study. J Clin Oncol 16:2007-2017, 1998
28. Spengler BA, Lazarova DL, Ross RA, et al: Cell lineage and differentiation state are primary determinants of MYCN gene expression and malignant potential in human neuroblastoma cells. Oncol Res 9:467-476, 1997
29. Ragnarsson G. Sigurdsson A, Eiriksdottir G, et al: Loss of heterozygosity at chromosome 1p in human breast cancer: Association with high S-phase, reduced patient survival and deletions at other chromosome regions. Int J Oncol 9:731-736, 1996
30. Schleiermacher G, Peter M, Michon J, et al: Two distinct deleted regions on the short arm of chromosome 1 in neuroblastoma. Genes Chromosomes Cancer 10:275-281, 1994
31. Kaplan EL, Meier EP: Nonparametric estimation from incomplete observation. J Am Stat Assoc 53:457-481, 1958
32. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
33. Healy KC: Telomere dynamics and telomerase activation in tumor progression: Prospects for prognosis and therapy. Oncol Res 7:121-130, 1995
34. Hisatomi H, Nagao K, Kanamaru T, et al: Levels of telomerase catalytic subunit mRNA as a predictor of potential malignancy. Int J Oncol 14:727-732, 1999
35. Xu D, Gruber A, Bjorkholm M, et al: Suppression of telomerase reverse transcriptase (hTERT) expression in differentiated HL-60 cells: Regulatory mechanisms. Br J Cancer 80:1156-1161, 1999
36. Wada E, Hisatomi H, Moritoyo T, et al: Genetic diagnostic test of hepatocellular carcinoma by telomerase catalytic subunit mRNA. Oncol Rep 5:1407-1412, 1998
37. Hiyama E, Hiyama K, Yokoyama T, et al: Rapid detection of MYCN gene amplification and telomerase expression in neuroblastoma. Clin Cancer Res 5:601-609, 1999
38. Hiyama T, Yokozaki H, Kitadai Y, et al: Overexpression of human telomerase RNA is an early event in oesophageal carcinogenesis. Virchows Arch 434:483-487, 1999
39. Maitra A, Yashima K, Rathi A, et al: The RNA component of telomerase as a marker of biologic potential and clinical outcome in childhood neuroblastic tumors. Cancer 85:741-749, 1999